RADX

Radiopharm Theranostics Limited American Depositary Shares

Radiopharm Theranostics Limited American Depositary Shares (RADX) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (C+); its weakest is Revisions (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
C+
Factor Score 2.7 / 5.0
Growth
C+
Factor Score 2.8 / 5.0
Profitability
C+
Factor Score 2.6 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 2.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA 0.0
Rev Growth YoY 154.5%
Gross Margin N/M
Price Return 3M -26.2%
Price Return 12M -32.1%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 1.5
ROE -92.1%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-03 C+ (2.7) C+ (2.8) C+ (2.6) C (2.4) C- (2.0) C+ (2.5)